Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Accumulated Expenses (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Accumulated Expenses for 11 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 38.0% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 38.0% year-over-year, with the annual reading at $1.1 billion for FY2025, 38.0% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.1 billion at BeOne Medicines, up from $1.0 billion in the prior quarter.
  • The five-year high for Accumulated Expenses was $1.1 billion in Q4 2025, with the low at $312.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $602.5 million, with a median of $563.7 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses skyrocketed 91.83% in 2021, then grew 0.17% in 2023.
  • Over 5 years, Accumulated Expenses stood at $558.1 million in 2021, then rose by 11.01% to $619.5 million in 2022, then increased by 11.99% to $693.7 million in 2023, then rose by 15.85% to $803.7 million in 2024, then surged by 38.0% to $1.1 billion in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.1 billion, $1.0 billion, and $908.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.